SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
Triple meeting 2024 – Aktis radiotherapy heads for the clinic
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
Ipsen casts doubt on Pfizer’s prostate plan
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
KRAS strikes back
First-in-human trial initiations reveal four KRAS assets.
